Well, the FDA “expert” panel met and came to a decision……..they couldn’t decide what, definitively, to do about Avandia. They panel was split in their opinions to either pull it altogether, leave it as is, or leave it on the market with stronger warnings and prescribing precautions. Now the matter goes to the FDA to make the final decision. Stay tuned for what the final outcome is!
Follow up on Avandia
Previous post: A good article on back pain management
Next post: Disruptive behavior and paient safety
